[
  {
    "ts": null,
    "headline": "BMO cuts rating on Merck and Biogen, on lack of near term catalyst",
    "summary": "Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.",
    "url": "https://finnhub.io/api/news?id=d059b0bd5c61e2c8c0d94c46c4569ffcaf65d5bf70d191364489f84223618cf3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734705894,
      "headline": "BMO cuts rating on Merck and Biogen, on lack of near term catalyst",
      "id": 132077718,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.",
      "url": "https://finnhub.io/api/news?id=d059b0bd5c61e2c8c0d94c46c4569ffcaf65d5bf70d191364489f84223618cf3"
    }
  },
  {
    "ts": null,
    "headline": "Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain",
    "summary": "It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen 15...",
    "url": "https://finnhub.io/api/news?id=50669773683a4176018453a2f712aafd4bb9b96e08058903b7a517c1d10843c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734703228,
      "headline": "Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain",
      "id": 132077719,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen 15...",
      "url": "https://finnhub.io/api/news?id=50669773683a4176018453a2f712aafd4bb9b96e08058903b7a517c1d10843c6"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=78a4d93ea35a51e02ea775dbe6806bf092342bfb76d56199e5e63a143630868d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734703217,
      "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
      "id": 132077721,
      "image": "https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=78a4d93ea35a51e02ea775dbe6806bf092342bfb76d56199e5e63a143630868d"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?",
    "summary": "We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into […]",
    "url": "https://finnhub.io/api/news?id=c7097abec9d755e18a3492e27e76a2cde4a27db4d80e7d2a6d50bb9aa3eb1a26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734696746,
      "headline": "Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now?",
      "id": 132077722,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Cheap NYSE Stocks To Invest In Now. In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other cheap NYSE stocks to invest in now. The stock market appears poised for another year of impressive returns, likely extending into […]",
      "url": "https://finnhub.io/api/news?id=c7097abec9d755e18a3492e27e76a2cde4a27db4d80e7d2a6d50bb9aa3eb1a26"
    }
  },
  {
    "ts": null,
    "headline": "Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody",
    "summary": "RAHWAY, N.J., December 20, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299.",
    "url": "https://finnhub.io/api/news?id=74af8e879c1322f5a3676016c22448ff2f8011f84f07d99d8e414aacb8b6746b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734695100,
      "headline": "Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody",
      "id": 132077723,
      "image": "https://media.zenfs.com/en/business-wire.com/bc03026a75ff1b5c6fd81a7a3305df99",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 20, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. As previously announced, Merck will develop, manufacture and commercialize LM-299.",
      "url": "https://finnhub.io/api/news?id=74af8e879c1322f5a3676016c22448ff2f8011f84f07d99d8e414aacb8b6746b"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Downgrades Merck (MRK)",
    "summary": "BMO Capital Downgrades Merck (MRK)",
    "url": "https://finnhub.io/api/news?id=eda427677d67d5be7fbb1e86eb062a44c5657bf769cb7d7cb3bdfb12b47fd0b4",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734690892,
      "headline": "BMO Capital Downgrades Merck (MRK)",
      "id": 132070236,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eda427677d67d5be7fbb1e86eb062a44c5657bf769cb7d7cb3bdfb12b47fd0b4"
    }
  },
  {
    "ts": null,
    "headline": "Merck: LM-299 antibody agreement finalized",
    "summary": "Merck announced on Friday that it had finalized a worldwide licensing agreement for the takeover of LM-299, a new antibody discovered by China's LaNova Medicines.In a press release, the US...",
    "url": "https://finnhub.io/api/news?id=cd66da7e258225779fe356938cc8efdd98c67a29f627c2ce2097b2a741ce0796",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734690742,
      "headline": "Merck: LM-299 antibody agreement finalized",
      "id": 132074244,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced on Friday that it had finalized a worldwide licensing agreement for the takeover of LM-299, a new antibody discovered by China's LaNova Medicines.In a press release, the US...",
      "url": "https://finnhub.io/api/news?id=cd66da7e258225779fe356938cc8efdd98c67a29f627c2ce2097b2a741ce0796"
    }
  }
]